This article is more than 5 years old. Information may no longer be current.
Zotarolimus-eluting stent exceeded bare metal stent in revascularization rate
Mauri L. J Am Coll Cardiol Intv. 2010;3:1240 -1249.
Click Here to Manage Email Alerts
Rates of target lesion revascularization at 5 years favored zotarolimus-eluting stents when compared with bare metal stents, without any increased risk of other adverse events reported for patients treated with zotarolimus-eluting stents, data from a meta-analysis suggested.
The study population featured patients from six prospective, randomized, single-arm multicenter trials that were treated with zotarolimus-eluting stents (Endeavor, Medtronic; n=2,132) and bare metal stents (control; n=596). Minimum duration of dual antiplatelet therapy was 3 to 6 months for both stent types.
At 5 years, follow-up was completed in 1,256 patients, with 97% of these patients eligible. Averse events at 5 years in the zotarolimus-eluting stent group when compared with the control were 5.9% vs. 7.6% for death; 2.4% vs. 3.7% for cardiac death; 3.4% vs. 4.8% for MI; and 0.8% vs. 1.7% for stent thrombosis (definite or probable); with only differences in target lesion revascularization reaching statistical significant (7% vs. 16.5%; P<.001).
“In this pooled analysis of clinical trial data examining the long-term safety of the zotarolimus-eluting stents, comparison to an analogous bare metal stents with propensity score adjustment showed no increase in rates of stent thrombosis, adverse cardiac events or mortality at 5 years of follow-up in the largest adjudicated dataset from registration trials of a drug-eluting stent,” the researchers wrote. “Prospectively designed randomized trials are required for definitive determination of safety compared with other drug-eluting stents.”
 |
Follow CardiologyToday.com on Twitter. |